Specific Trials Information

RegionDisease SiteStudy IDBrief DescriptionMDT Handbook
LeedsUrology111 Trial (formerly BEP 111)A single arm multi-centre study evaluating a single cycle of BEP as adjuvant chemotherapy in high risk, stage 1 non-seminomatous germ cell tumoursLeeds Urology
LeedsLiverABC-03Randomised phase II trial of cediranib (AZD2171) vs. placebo in addition to cisplatin/gemcitabine chemotherapy for
patients with advanced biliary tract cancers
Leeds Liver
LeedsHaematologyADMIREDoes the addition of mitoxantrone improve response? A randomised phase II trial of fludarabine, cyclophosphamide and rituximab mitoxantrone in previously untreated CLLLeeds Haematology
Calderdale & Huddersfield HaematologyADMIREDoes the addition of mitoxantrone improve response? A randomised phase II trial of fludarabine, cyclophosphamide and rituximab mitoxantrone in previously untreated CLL.C&H Haematology
LeedsGynaecologyAdvocateAdvanced Ovarian Cancer: Care and Treatment ExperiencesLeeds Gynaecology
LeedsBreastAFFECTExamination of affected tissue of BRCA1 variant carriersLeeds Breast
LeedsPaediatricsALLR3An International Collaborative Trial for relapsed Refractory Acute Lymphoblastic Leukaemia (ALL)Leeds Paediatrics
YorkHaematologyAML 17Working parties on leukaemia in adults and children trial in acute myeloid leukaemia or high risk myelodysplastic syndrome 17York Haematology
Mid YorkshireHaematologyAML 17Working parties on leukaemia in adults and children trial in acute myeloid leukaemia or high risk myelodysplastic syndrome 17Mid Yorkshire Haematology
LeedsHaematologyAML 17Working parties on leukaemia in adults and children trial in acute myeloid leukaemia or high risk myelodysplastic syndrome 17Leeds Haematology
BradfordHaematologyAML 17Working parties on leukaemia in adults and children trial in acute myeloid leukaemia or high risk myelodysplastic syndrome 17Bradford Haematology
LeedsHaematologyAML 18 PilotA Phase 1B/2 Study to Evaluate the Feasibility of combining either the Tyrosine kinase Inhibitor AC220, or the CXCR4
inhibitor Plerixafor with Chemotherapy in older patients with Acute Myeloid Leukaemia and Myelodysplastic Syndrome
in patients over 60 yea
Leeds Haematology
LeedsHaematologyARCTICA randomised, phase IIB trial in previously untreated patients with chronic lymphocytic leukaemia (CLL) to compare fludarabine, cyclophosphamide and rituximab (FCR) with FC, mitoxantrone and low dose rituximab (FCM-miniR)Leeds Haematology
HarrogateHaematologyARCTICA randomised, phase IIB trial in previously untreated patients with chronic lymphocytic leukaemia (CLL) to compare fludarabine, cyclophosphamide and rituximab (FCR) with FC, mitoxantrone and low dose rituximab (FCM-miniR)Harrogate Haematology
Mid YorkshireHaematologyARCTICA randomised, phase IIB trial in previously untreated patients with chronic lymphocytic leukaemia (CLL) to compare fludarabine, cyclophosphamide and rituximab (FCR) with FC, mitoxantrone and low dose rituximab (FCM-miniR)Mid Yorkshire Haematology
BradfordColorectalAristotleA phase III trial comparing standard versus novel CRT as pre-operative treatment for MRI defined locally advanced rectal
cancer
Bradford Colorectal
YorkColorectalAristotleA phase III trial comparing standard versus novel CRT as pre-operative treatment for MRI defined locally advanced rectal
cancer
York Colorectal
LeedsColorectalAristotleA phase III trial comparing standard versus novel CRT as pre-operative treatment for MRI defined locally advanced rectal
cancer
Leeds Colorectal
AiredaleColorectalAristotleA phase III trial comparing standard versus novel CRT as pre-operative treatment for MRI defined locally advanced rectal
cancer
Airedale Colorectal
Calderdale & HuddersfieldColorectalAristotleA phase III trial comparing standard versus novel CRT as pre-operative treatment for MRI defined locally advanced rectal
cancer
C&H Colorectal
Mid YorkshireColorectalAristotleA phase III trial comparing standard versus novel CRT as pre-operative treatment for MRI defined locally advanced rectal
cancer
Mid Yorkshire Colorectal
LeedsHead & NeckART DECOA Randomised Multicentre Accelerated Radiotherapy Study of Dose Escalated Intensity Modulated Radiotherapy vs
Standard Dose Intensity Modulated Radiotherapy in Patients Receiving Treatment for Locally Advanced Laryngeal and
Hypopharyngeal Cancers.
Leeds Head & Neck
YorkHead & NeckART DECOA Randomised Multicentre Accelerated Radiotherapy Study of Dose Escalated Intensity Modulated Radiotherapy vs
Standard Dose Intensity Modulated Radiotherapy in Patients Receiving Treatment for Locally Advanced Laryngeal and
Hypopharyngeal Cancers.
York Head & Neck
LeedsBreastARTemisAvastin Randomised Trial with neo-adjuvant chemotherapy for patients with early HER 2 negative breast cancer.Leeds Breast
LeedsPaediatricsAT9283 in children and adolescents with acute leukemiaA Cancer Research UK Phase I trial of AT9283 (a selective inhibitor of aurora kinases) given over 72 hours every 21 days
via intravenous infusion in children and adolescents aged 6 months to 18 years with relapsed and refractory acute
leukaemia
Leeds Paediatrics
LeedsSkinAVAST-MAdjuvant aVAStin Trial in high risk Melanoma - A randomised trial evaluating the VEGF inhibitor, bevacizumab (Avastin®),as adjuvant therapy following resection of AJCC stage IIB (T3bN0M0 & T4aN0M0), IIC (T4bN0M0) and III (TxN1-3M0) cutaneous melanomaMelanoma/Skin
LeedsLiverBILCAPA randomised clinical trial evaluating adjuvant chemotherapy with capecitabine compared to expectant treatment alone following surgery for biliary tract cancerLeeds Liver
Calderdale & HuddersfieldUpper GIBILCAPA randomised clinical trial evaluating adjuvant chemotherapy with capecitabine compared to expectant treatment alone following surgery for biliary tract cancerC&H Upper GI
Mid YorkshireUrologyBOXITBOXITMid Yorkshire Urology
Calderdale & HuddersfieldUrologyBOXITBOXITC&H Urology
LeedsUrologyBOXITBOXITLeeds Urology
LeedsBreastBreast cancer, sexuality and intimacyA semi structured interview study to explore the sexual problems experienced by women diagnosed with breast cancer
and to examine the support services available to help women manage sexual problems
Leeds Breast
LeedsHaematologyCHOP-ORSingle arm NCRI feasibility study of CHOP in combination with Ofatumumab in induction and maintenance for patients
with newly diagnosed Richter’s Syndrome
Leeds Haematology
Mid YorkshireUpper GIChOPINChemoprevention of premalignant intestinal neoplasia (ChOPIN) incorporating inherited predisposition of neoplasia
(IPOD) analysis of genomic DNA from AspECT and BOSS clinical trials. It also incorporates patients undergoing genomic
assessment independent
Mid Yorkshire Upper GI
YorkUpper GIChOPINChemoprevention of premalignant intestinal neoplasia (ChOPIN) incorporating inherited predisposition of neoplasia
(IPOD) analysis of genomic DNA from AspECT and BOSS clinical trials. It also incorporates patients undergoing genomic
assessment independent
York Upper GI
HarrogateUpper GIChOPINChemoprevention of premalignant intestinal neoplasia (ChOPIN) incorporating inherited predisposition of neoplasia
(IPOD) analysis of genomic DNA from AspECT and BOSS clinical trials. It also incorporates patients undergoing genomic
assessment independent
Harrogate Upper GI
LeedsGynaecologyCIRCCaCediranib In Recurrent Cervical Cancer - A Randomised Double Blind Phase II trial of carboplatin-paclitaxel plus cediranib versus carboplatin-paclitaxel plus placebo in metastatic/recurrent cervical cancerLeeds Gynaecology
LeedsHaematologyCLEARA phase II trial of broad spectrum antibiotic therapy for early stage, non-progressive chronic lymphocytic leukaemia
without adverse prognostic factors
Leeds Haematology
LeedsPaediatricsCNS 2004 03Cooperative Multicentre Study For Children And Adolescents With Low Grade Glioma (CNS 2004 03)Leeds Paediatrics
BradfordLungCONVERTA 2-arm randomised controlled trial of concurrent chemo-radiotherapy comparing twice-daily and once-daily radiotherapy schedules in patients with limited stage small cell lung cancer (SCLC) and good performance statusBradford Lung
LeedsLungCONVERTA 2-arm randomised controlled trial of concurrent chemo-radiotherapy comparing twice-daily and once-daily radiotherapy schedules in patients with limited stage small cell lung cancer (SCLC) and good performance statusLeeds Lung
HarrogateLungCONVERTA 2-arm randomised controlled trial of concurrent chemo-radiotherapy comparing twice-daily and once-daily radiotherapy schedules in patients with limited stage small cell lung cancer (SCLC) and good performance statusHarrogate Lung
LeedsBreastCOPEDiagnostic and therapeutic insights into breast cancer from morphological and molecular profiling of breast tumours in
patients with germline p53 mutations (Li Fraumeni Syndrome)
Leeds Breast
LeedsHead and NeckCoSTARCOchlear Sparing Therapy And conventional Radiation: A Multicentre Randomised Study Of Cochlear Sparing Intensity Modulated Radiotherapy Versus Conventional Radiotherapy In Patients With Parotid TumoursLeeds Head & Neck
BradfordColorectalCReSTThe role of endoluminal stenting in the acute management of obstructing colorectal cancerBradford Colorectal
HarrogateColorectalCReSTThe role of endoluminal stenting in the acute management of obstructing colorectal cancerHarrogate Colorectal
LeedsColorectalCReSTThe role of endoluminal stenting in the acute management of obstructing colorectal cancerLeeds Colorectal
Mid YorkshireColorectalCReSTThe role of endoluminal stenting in the acute management of obstructing colorectal cancerMid Yorkshire Colorectal
LeedsPaediatricsCRUK/CCLG AT9283 in Paediatric PatientsA CCLG/Cancer Research UK Phase I Trial of AT9283 (a selective inhibitor of Aurora kinases) given for 72 hours every 21
days via intravenous infusion in children and adolescents with relapsed and refractory solid tumours.
Leeds Paediatrics
LeedsBreastCR UK Stratified Medicine Pilot StudyThe Cancer Research UK Stratified Medicine Programme: Pilot StudyLeeds Breast
LeedsSkinCR UK Stratified Medicine Pilot StudyThe Cancer Research UK Stratified Medicine Programme: Pilot StudyMelanoma/Skin
LeedsGynaecologyCR UK Stratified Medicine Pilot StudyThe Cancer Research UK Stratified Medicine Programme: Pilot StudyLeeds Gynaecology
LeedsHaematologyDEC-MDSUse of Decitabine in Myelodysplastic Syndromes (MDS) Following Azacitidine (AZA) FailureLeeds Haematology
BradfordGynaecologyDNA Methylation StudyDNA Methylation as a predictor for response and progression free survival in patients with ovarian cancerBradford Gynaecology
LeedsGynaecologyDNA Methylation StudyDNA Methylation as a predictor for response and progression free survival in patients with ovarian cancerLeeds Gynaecology
BradfordHaematologyEBV associated NK/T cell malignanciesStudy of EBV associated NK/T cell diseases and formation of a registryBradford Haematology
LeedsHaematologyEBV associated NK/T cell malignanciesStudy of EBV associated NK/T cell diseases and formation of a registryLeeds Haematology
LeedsBreastEMBRACEEpidemiological study of BRCA1 and BRCA2 mutation carriersLeeds Breast
Mid YorkshireBreastEPHOS-BEffect of Perioperative AntiHER-2 therapy on Early Breast Cancer Study – Biological phaseMid Yorkshire Breast
LeedsBreastEPHOS-BEffect of Perioperative AntiHER-2 therapy on Early Breast Cancer Study – Biological phaseLeeds Breast
LeedsPaediatricsEPOC Docorubicin in childrenPhase II pharmacokinetic study to assess the age-dependency in the clearance of doxorubicin in paediatric patients with
solid tumours and leukaemia
Leeds Paediatrics
LeedsPancreasESPAC-TplusESPAC-Tplus Translational Studies (Tissue sample collection from ESPAC Adjuvant Trials in Pancreatic Cancer)Leeds Pancreas
Calderdale & HuddersfieldUpper GIESPAC 4EUROPEAN STUDY GROUP FOR PANCREATIC CANCER - TRIAL 4. Combination versus single agent chemotherapy in resectable pancreatic cancerC&H Upper GI
BradfordUpper GIESPAC 4EUROPEAN STUDY GROUP FOR PANCREATIC CANCER - TRIAL 4. Combination versus single agent chemotherapy in resectable pancreatic cancerBradford Upper GI
LeedsPancreasESPAC 4EUROPEAN STUDY GROUP FOR PANCREATIC CANCER - TRIAL 4. Combination versus single agent chemotherapy in resectable pancreatic cancerLeeds Pancreas
LeedsPaediatricsEsPhALLEuropean Intergroup Study on Post Induction Treatment of Philadelphia Positive Acute Lymphoblastic Leukaemia with ImatinibLeeds Paediatrics
LeedsPaediatricsET 2000 03European Ewing Tumour Working Initiatives of National Groups: Ewing Tumour Studies 1999Leeds Paediatrics
Calderdale & HuddersfieldLungET TrialA multicentre, randomised, phase III trial of platinum-based chemotherapy versus non-platinum chemotherapy, after ERCC1 stratification, in patients with advanced/metastatic non-small cell lung cancerC&H Lung
LeedsPaediatricsEuroNet PHL-C1 Hodgkin'sFirst International Inter-Group Study for Classical Hodgkin’s Lymphoma in Children and AdolescentsLeeds Paediatrics
LeedsUrologyEuropean Trial of Free Light Chain Removal by Extended Haemodialysis in CastEuropean Trial of Free Light Chain Removal by Extended Haemodialysis in Cast NephropathyLeeds Urology
BradfordUrologyEuropean Trial of Free Light Chain Removal by Extended Haemodialysis in CastEuropean Trial of Free Light Chain Removal by Extended Haemodialysis in Cast NephropathyBradford Urology
LeedsUrologyEvaluation of Biomarkers for Prognosis of Renal Cell CarcinomaEvaluation of Biomarkers for Prognosis and Monitoring in Patients with Renal Cell CarcinomaLeeds Urology
BradfordBreastExploring the needs of breast cancer survivors after treatmentExploring the emotional, social and functional needs of women living with breast cancer following hospital based
treatment: A study to identify unmet needs across different ethnic groups and socioeconomic backgrounds: Version One.
Bradford Breast
LeedsPaediatricsFACT studyFactors associated with Childhood Tumours StudyLeeds Paediatrics
LeedsBreastFBCSIdentification and molecular analyses of families with susceptibility to breast cancerLeeds Breast
AiredaleBreastFH02Mammographic surveillance in women aged 35-39 at enhanced familial risk of breast cancer (FH02)Airedale Breast
LeedsBreastFH02Mammographic surveillance in women aged 35-39 at enhanced familial risk of breast cancer (FH02)Leeds Breast
BradfordBreastFH02Mammographic surveillance in women aged 35-39 at enhanced familial risk of breast cancer (FH02)Bradford Breast
LeedsColorectalFollow up to MOSAIC studyA non-interventional follow-up to the MOSAIC study (multicenter international study of oxaliplatin/5-
Fluorouracil/leucovorin in the adjuvant treatment of colon cancer) up to 10 years, and translational research
Leeds Colorectal
LeedsColorectalFOXFIREAn open-label randomised phase III trial 5-Fluorouracil, OXaliplatin and Folinic acid +/- Interventional Radio-
Embolisation as first line treatment for patients with unresectable liver-only or liver-predominant metastatic colorectal
cancer
Leeds Colorectal
Calderdale & HuddersfieldColorectalFOxTROTFluoropyrimidine, Oxaliplatin & Targeted Receptor pre-Operative Therapy for colon cancer. A randomised trial assessing
whether preoperative chemotherapy and/or an anti-EGFR monoclonal antibody improve outcome in high-risk operable
colon cancer.
C&H Colorectal
LeedsColorectalFOxTROTFluoropyrimidine, Oxaliplatin & Targeted Receptor pre-Operative Therapy for colon cancer. A randomised trial assessing
whether preoperative chemotherapy and/or an anti-EGFR monoclonal antibody improve outcome in high-risk operable
colon cancer.
Leeds Colorectal
HarrogateColorectalFOxTROTFluoropyrimidine, Oxaliplatin & Targeted Receptor pre-Operative Therapy for colon cancer. A randomised trial assessing
whether preoperative chemotherapy and/or an anti-EGFR monoclonal antibody improve outcome in high-risk operable
colon cancer.
Harrogate Colorectal
YorkColorectalFOxTROTFluoropyrimidine, Oxaliplatin & Targeted Receptor pre-Operative Therapy for colon cancer. A randomised trial assessing
whether preoperative chemotherapy and/or an anti-EGFR monoclonal antibody improve outcome in high-risk operable
colon cancer.
York Colorectal
Mid YorkshireColorectalFOxTROTFluoropyrimidine, Oxaliplatin & Targeted Receptor pre-Operative Therapy for colon cancer. A randomised trial assessing
whether preoperative chemotherapy and/or an anti-EGFR monoclonal antibody improve outcome in high-risk operable
colon cancer.
Mid Yorkshire Colorectal
BradfordColorectalFOxTROTFluoropyrimidine, Oxaliplatin & Targeted Receptor pre-Operative Therapy for colon cancer. A randomised trial assessing
whether preoperative chemotherapy and/or an anti-EGFR monoclonal antibody improve outcome in high-risk operable
colon cancer.
Bradford Colorectal
LeedsPaediatricsGeDDiSA prospective randomised controlled phase III trial of gemcitabine and docetaxel compared with doxorubicin as first line
treatment in previously untreated advanced unresectable or metastatic soft tissue sarcomas
Leeds Paediatrics
LeedsGynaecologyGROINSS-V IIGROningen INternational Study on Sentinel nodes in Vulvar cancer (GROINSS-V) IILeeds Gynaecology
YorkHead & NeckHeadandNeck5000Evaluation of centralisation in head and neck cancerYork Head & Neck
LeedsHead & NeckHeadandNeck5000Evaluation of centralisation in head and neck cancerLeeds Head & Neck
LeedsHead and NeckHopOnHOPON (Hyperbaric Oxygen for the Prevention of Osteoradionecrosis): A Randomised Controlled Trial of Hyperbaric Oxygen to prevent Osteoradionecrosis of the Irradiated MandibleLeeds Head & Neck
BradfordHead & NeckHopOnHOPON (Hyperbaric Oxygen for the Prevention of Osteoradionecrosis): A Randomised Controlled Trial of Hyperbaric Oxygen to prevent Osteoradionecrosis of the Irradiated MandibleBradford Head & Neck
BradfordUrologyHOT IIRandomised double-blind controlled phase III trial of hyperbaric oxygen therapy in patients suffering long-term adverse effects of radiotherapy for pelvic cancerBradford Urology
LeedsUrologyHOT IIRandomised double-blind controlled phase III trial of hyperbaric oxygen therapy in patients suffering long-term adverse effects of radiotherapy for pelvic cancerLeeds Urology
YorkBreastICICLEA study to Investigate the genetiCs of In situ Carcinoma of the ductaL subtypEYork Breast
AiredaleGynaecologyICON 8ICON8: An international phase III randomised trial of dose-fractionated chemotherapy compared to standard threeweekly
chemotherapy, following immediate primary surgery or as part of delayed primary surgery, for women with
newly diagnosed epithelial ovari
Airedale Gynaecology
Calderdale & HuddersfieldGynaecologyICON 8ICON8: An international phase III randomised trial of dose-fractionated chemotherapy compared to standard threeweekly
chemotherapy, following immediate primary surgery or as part of delayed primary surgery, for women with
newly diagnosed epithelial ovari
C&H Gynaecology
BradfordGynaecologyICON 8ICON8: An international phase III randomised trial of dose-fractionated chemotherapy compared to standard threeweekly
chemotherapy, following immediate primary surgery or as part of delayed primary surgery, for women with
newly diagnosed epithelial ovari
Bradford Gynaecology
LeedsHaematologyIELSG 26A clinico-pathologic study of Primary Mediastinal B-cell lymphomaLeeds Haematology
BradfordBreastIMPORT HIGHRandomised trial testing dose escalated intensity modulated radiotherapy in women with higher than average local
tumour recurrence risk after breast conservation surgery and appropriate systemic therapy for early breast cancer
Bradford Breast
LeedsBreastIMPORT HIGHRandomised trial testing dose escalated intensity modulated radiotherapy in women with higher than average local
tumour recurrence risk after breast conservation surgery and appropriate systemic therapy for early breast cancer
Leeds Breast
LeedsHaematologyIntestinal t-cell trial (ITCL)A phase II evaluation of high dose chemotherapy and autologous bone marrow transplantation for intestinal T cell lymphomasLeeds Haematology
LeedsUpper GIIrvalecPhase Ib/II, multicentre, open-label, randomized, clinical study with dose optimization of two different schedules of
Elisidepsin Trifluoroacetate (Irvalec) as a single agent in patients with unresectable, locally advanced or metastatic
Esophageal, Esopha
Leeds Upper GI
LeedsUpper GIIrvalec® in Metastatic or Advanced Gastric/Esophageal cancer v. 1.0Phase Ib/II, multicentre, open-label, randomized, clinical study with dose optimization of two different schedules of Elisidepsin Trifluoroacetate (Irvalec) as a single agent in patients with unresectable, locally advanced or metastatic Esophageal, EsophaLeeds Upper GI
LeedsUrologyLaMBLaMB – a phase II/III, randomised, two-arm comparison of maintenance lapatinib versus placebo after first-line chemotherapy in patients with HER1 and/or HER2 overexpressing locally advanced or metastatic bladder cancerLeeds Urology
Calderdale & HuddersfieldUrologyLaMBLaMB – a phase II/III, randomised, two-arm comparison of maintenance lapatinib versus placebo after first-line chemotherapy in patients with HER1 and/or HER2 overexpressing locally advanced or metastatic bladder cancerC&H Urology
Calderdale & HuddersfieldBreastLANTERNA randomised phase II screening trial with functional imaging and patient reported toxicity sub-studies comparing
LApatiNib plus capecitabine versus continued Trastuzumab plus capecitabine after local therapy in patients with ERb B2
positive metastatic br
C&H Breast
LeedsBreastLANTERNA randomised phase II screening trial with functional imaging and patient reported toxicity sub-studies comparing
LApatiNib plus capecitabine versus continued Trastuzumab plus capecitabine after local therapy in patients with ERb B2
positive metastatic br
Leeds Breast
AiredaleBreastLATTELong-term Anatrozole vs. Tamoxifen Treatment EffectsAiredale Breast
LeedsBreastLATTELong-term Anatrozole vs. Tamoxifen Treatment EffectsLeeds Breast
Calderdale & HuddersfieldBreastLATTELong-term Anatrozole vs. Tamoxifen Treatment EffectsC&H Breast
BradfordBreastLATTELong-term Anatrozole vs. Tamoxifen Treatment EffectsBradford Breast
YorkBreastLATTELong-term Anatrozole vs. Tamoxifen Treatment EffectsYork Breast
LeedsPaediatricsLEG 2004 06Study to investigate lung function following pulmonary radiotherapy in Wilms tumour survivors (LEG 2004 06)Leeds Paediatrics
LeedsHaematologyLenaRICPhase II study of the adjuvant use of lenalidomide in patients undergoing reduced intensity conditioning allogenic
transplantation for multiple myeloma
Leeds Haematology
BradfordHaematologyLI-1Leukaemia Lymphoma Research and NCRI Working Group Pick a Winner Programme (LI1) TrialBradford Haematology
AiredaleHaematologyLI-1Leukaemia Lymphoma Research and NCRI Working Group Pick a Winner Programme (LI1) TrialAiredale Haematology
BradfordHead & NeckLIHNCSA prospective, multi-centre, randomised controlled trial looking at the effectiveness of Lugol's Iodine to assist excision of marginal dysplasia at resection of oral and oropharyngeal squamous cell carcinoma.Bradford Head & Neck
YorkHead & NeckLIHNCSA prospective, multi-centre, randomised controlled trial looking at the effectiveness of Lugol's Iodine to assist excision of marginal dysplasia at resection of oral and oropharyngeal squamous cell carcinoma.York Head & Neck
LeedsPaediatricsLK 2006 10International collaborative treatment protocol for infants under one year with acute lymphoblastic or biphenotypic
leukaemia
Leeds Paediatrics
LeedsLungLungCASTDoes smoking status after being diagnoses with lung cancer influence outcome? An observational cohort study
alongisde a randomised trial of different smoking cessation interventions
Leeds Lung
Calderdale & HuddersfieldLungLungCASTDoes smoking status after being diagnoses with lung cancer influence outcome? An observational cohort study
alongisde a randomised trial of different smoking cessation interventions
C&H Lung
Mid YorkshireLungMALCSA population based case-control study of mesothelioma and lung cancer in relation to occupation among British men and womenMid Yorkshire Lung
AiredaleLungMALCSA population based case-control study of mesothelioma and lung cancer in relation to occupation among British men and womenAiredale Lung
YorkLungMALCSA population based case-control study of mesothelioma and lung cancer in relation to occupation among British men and womenYork Lung
LeedsLungMALCSA population based case-control study of mesothelioma and lung cancer in relation to occupation among British men and womenLeeds Lung
HarrogateLungMALCSA population based case-control study of mesothelioma and lung cancer in relation to occupation among British men and womenHarrogate Lung
Calderdale & HuddersfieldLungMALCSA population based case-control study of mesothelioma and lung cancer in relation to occupation among British men and womenC&H Lung
LeedsHaematologyMARALLPhase I/II Study combining humanised anti-CD20 (veltuzumab), anti-CD22 (epratuzumab) and both monoclonal
antibodies with chemotherapy in adults with recurrent or refractory B-precursor acute lymphoblastic leukaemia (ALL)
Leeds Haematology
Calderdale & Huddersfield HaematologyMDS BIOMolecular and functional characterisation of bone marrow function in normal subjects, myelodysplastic syndromes (MDS), acute myeloid leukaemia (AML) and secondary disorders of haematopoiesisC&H Haematology
LeedsHaematologyMDS BIOMolecular and functional characterisation of bone marrow function in normal subjects, myelodysplastic syndromes (MDS), acute myeloid leukaemia (AML) and secondary disorders of haematopoiesisLeeds Haematology
AiredaleSkinMelanoma Cohort StudyThe Melanoma Follow-Up and Case-Control Family StudyMelanoma/Skin
YorkSkinMelanoma Cohort StudyThe Melanoma Follow-Up and Case-Control Family StudyMelanoma/Skin
HarrogateSkinMelanoma Cohort StudyThe Melanoma Follow-Up and Case-Control Family StudyMelanoma/Skin
BradfordSkinMelanoma Cohort StudyThe Melanoma Follow-Up and Case-Control Family StudyMelanoma/Skin
LeedsSkinMelanoma Cohort StudyThe Melanoma Follow-Up and Case-Control Family StudyMelanoma/Skin
Calderdale & HuddersfieldSkinMelanoma Cohort StudyThe Melanoma Follow-Up and Case-Control Family StudyMelanoma/Skin
LeedsGynaecologymEOCA GCIG Intergroup multicentre trial of open label carboplatin and paclitaxel +/- bevacizumab compared with oxaliplatin and capecitabine +/- bevacizumab as first line chemotherapy in patients with mucinous Epithelial Ovarian CancerLeeds Gynaecology
LeedsHaematologyMiniAlloPhase II study of low intensity allogeneic transplantation in Mantle Cell LymphomaLeeds Haematology
Mid YorkshireHaematologyMyeloma XIRandomised comparisons in myeloma patients of all ages of thalidomide, lenalidomide and bortezomib combinations and maintenance lenalidomideMid Yorkshire Haematology
HarrogateHaematologyMyeloma XIRandomised comparisons in myeloma patients of all ages of thalidomide, lenalidomide and bortezomib combinations and maintenance lenalidomideHarrogate Haematology
Calderdale & Huddersfield HaematologyMyeloma XIRandomised comparisons in myeloma patients of all ages of thalidomide, lenalidomide and bortezomib combinations and maintenance lenalidomideC&H Haematology
YorkHaematologyMyeloma XIRandomised comparisons in myeloma patients of all ages of thalidomide, lenalidomide and bortezomib combinations and maintenance lenalidomideYork Haematology
LeedsHaematologyMyeloma XIRandomised comparisons in myeloma patients of all ages of thalidomide, lenalidomide and bortezomib combinations and maintenance lenalidomideLeeds Haematology
BradfordHaematologyMyeloma XIRandomised comparisons in myeloma patients of all ages of thalidomide, lenalidomide and bortezomib combinations and maintenance lenalidomideBradford Haematology
LeedsHaematologyMyeloma X RelapseA phase III study to determine the role of a second autologous stem cell transplant as consolidation therapy in patients
with relapsed multiple myeloma following prior high-dose chemotherapy and autologous stem cell rescue.
Leeds Haematology
Mid YorkshireHaematologyMyeloma X RelapseA phase III study to determine the role of a second autologous stem cell transplant as consolidation therapy in patients
with relapsed multiple myeloma following prior high-dose chemotherapy and autologous stem cell rescue.
Mid Yorkshire Haematology
BradfordHaematologyMyeloma X RelapseA phase III study to determine the role of a second autologous stem cell transplant as consolidation therapy in patients
with relapsed multiple myeloma following prior high-dose chemotherapy and autologous stem cell rescue.
Leeds Haematology
LeedsPaediatricsNB 2002 06High Risk Neuroblastoma Study 1 of SIOP-EuropeLeeds Paediatrics
LeedsHaematologyNCRN069 ORCHARRDOfatumumab versus Rituximab Salvage Chemoimmunotherapy followed by ASCT in Relapsed or Refractory DLBCLLeeds Haematology
LeedsBreastNCRN113 D-CAREA Randomised, Double-Blind, Placebo-Controlled, Multi-Centre Phase 3 Study of Denosumab as Adjuvant Treatment for
Women with Early-Stage Breast Cancer at High Risk of Recurrence (D-CARE)
Leeds Breast
LeedsHaematologyNCRN132An Open-Label, Dose Escalation, Multicenter Phase 1/2 Study of KW-2478 in Combination with Bortezomib in Subjects
with Relapsed and/or Refractory Multiple Myeloma
Leeds Haematology
LeedsHaematologyNCRN133 (TELESTO)A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Clinical Trial Of Deferasirox In Patients With Myelodysplastic Syndromes (Low/Int-1 Risk) And Transfusional Iron Overload (Telesto)Leeds Haematology
Calderdale & HuddersfieldBreastNCRN155 - ISICAInternational Study of Incident Cancer (ISICA) - breast cancer and diabetesC&H Breast
LeedsHaematologyNCRN171AL YPMHASPEH 2O/3 MMUALTICENTER, RANDOMIZED OPENLABEL STUDY TO COMPARE THE EFFICACY AND SAFETY OF
LENALIDOMIDE (REVLIMID®) VERSUS INVESTIGATOR’S CHOICE IN PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE
LARGE B-CELL LYMPHOMA
Leeds Haematology
Calderdale & HuddersfieldBreastNCRN186 ALTERNATIVEA Phase III trial to compare the safety and efficacy of lapatinib plus trastuzumab plus an aromatase inhibitor (AI) versus
trastuzumab plus an AI versus lapatinib plus an AI as first-line therapy in postmenopausal subjects with hormone
receptor positive,
C&H Breast
LeedsHaematologyNCRN188Randomized, open label, multicenter phase III study of Efficacy and Safety in POlycythemia vera subjects who are
resistant to or intolerant of hydroxyurea: JAK iNhibitor INC424 tablets verSus bEst available care (The RESPONSE Trial)
Leeds Haematology
LeedsUrologyNCRN211 - IMPRINTA randomized, controlled Phase III study investigating IMA901 multipeptide cancer vaccine in patients receiving sunitinib
as first-line therapy for advanced/metastatic renal cell carcinoma
Leeds Urology
LeedsHaematologyNCRN237ORpeelna-lpabseel,d M Aulnti-dce Rnteerf,r saincgtleo-arrym M stuMdy for the safety and efficacy of Pomalidomide (CC-4047) Monotherapy for
Subjects with Refractory or Relapsed and Refractory Multiple Myeloma
Leeds Haematology
LeedsPaediatricsNCRN244A Randomized, Phase 2 Study of Single-agent Erlotinib versus Oral Etoposide in Patients with Recurrent or Refractory Pediatric EpendymomaLeeds Paediatrics
LeedsHaematologyNCRN246 GALLIUMAG Ma1ul0tic1e nOterr ,R Pihtausex I imi, Oapiennt-Leanbeal,n Rcanedomized Study In Previously Untreated Patients With Advanced Indolent Non-
Hodgkin's Lymphoma Comparing Ga101 (Ro5072759) Plus Chemotherapy With Rituximab Plus Chemotherapy Followed
By Ga101 Or Rituximab Maintenance
Leeds Haematology
LeedsBreastNCRN250 APHINITYAC aprospective, randomized multicenter, multinational, two-arm comparison of chemotherapy plus trastuzumab given
for a total of one year versus chemotherapy plus trastuzumab and pertuzumab given for a total of one year as adjuvant
therapy in patients
Leeds Breast
LeedsPaediatricsNCRN251OEppeenn-ladbyelm, Pohamsea 2 Study of Single-agent Erlotinib for Patients with Pediatric Ependymoma Previously Treated with Oral Etoposide in Protocol OSI-774-205Leeds Paediatrics
LeedsHaematologyNCRN253AA Plkhayslea 2t iSntugd yA tgo eAnsstesss the Efficacy and Safety of CAL-101 in Patients with Indolent B-Cell Non-Hodgkin Lymphoma
Refractory to Rituximab and Alkylating Agents
Leeds Haematology
LeedsPaediatricsNCRN259 HERBYA phase II open-label, randomized, multi-centre comparative study of bevacizumab-based therapy in paediatric patients
with newly diagnosed supratentorial high-grade glioma
Leeds Paediatrics
LeedsPancreasNCRN287Phase 2 Placebo-controlled Double-blind Trial of Dasatinib Added to Gemcitabine for Subjects with Locally-advanced
Pancreatic Cancer
Leeds Pancreas
LeedsHaematologyNCRN289 JAKARTAA Phase 3, Randomized, Double-Blinded, Placebo Controlled 3 arm Study of SAR302503 in Patients with Intermediate-2
or High Risk Primary (PMF), Post Polycythemia Vera (post PV-MF), or Post-Essential Thrombocythemia Myelofibrosis
(post ET-MF) with Splenomeg
Leeds Haematology
LeedsBreastNeoExcelNeoadjuvant trial of pre-operative exemestane or letrozole +/- celecoxib in the treatment of ER-positive
postmenopausal early breast cancer
Leeds Breast
Mid YorkshireColorectalNSCCGNational Study of Colorectal Cancer GeneticsMid Yorkshire Colorectal
LeedsColorectalNSCCGNational Study of Colorectal Cancer GeneticsLeeds Colorectal
AiredaleColorectalNSCCGNational Study of Colorectal Cancer GeneticsAiredale Colorectal
Calderdale & HuddersfieldColorectalNSCCGNational Study of Colorectal Cancer GeneticsC&H Colorectal
BradfordColorectalNSCCGNational Study of Colorectal Cancer GeneticsBradford Colorectal
HarrogateColorectalNSCCGNational Study of Colorectal Cancer GeneticsHarrogate Colorectal
YorkColorectalNSCCGNational Study of Colorectal Cancer GeneticsYork Colorectal
HarrogateHaematologyNSHLGNational Study of Hodgkin's Lymphoma GeneticsHarrogate Haematology
AiredaleHaematologyNSHLGNational Study of Hodgkin's Lymphoma GeneticsAiredale Haematology
BradfordHaematologyNSHLGNational Study of Hodgkin's Lymphoma GeneticsBradford Haematology
LeedsHaematologyNSHLGNational Study of Hodgkin's Lymphoma GeneticsLeeds Haematology
Mid YorkshireHaematologyNSHLGNational Study of Hodgkin's Lymphoma GeneticsMid Yorkshire Haematology
YorkHaematologyNSHLGNational Study of Hodgkin's Lymphoma GeneticsYork Haematology
LeedsHaematologyOfatumumab StudyPhase II Trial of Single Agent Ofatumumab in Relapsed / Refractoy Mantle Cell LymphomaLeeds Haematology
LeedsPaediatricsOTISA Phase II Study to determine the efficacy and safety of conventional dose Oral Treosulfan In patients with advanced pretreated
Ewing's Sarcoma
Leeds Paediatrics
Mid YorkshireHaematologyPACIFICOAlkylator Combination In Follicular lymphoma Immuno-Chemotherapy for Older patients: a phase III comparison of first-line R-CVP versus R-FC (previous acronym: RiCH FLO)Mid Yorkshire Haematology
LeedsHaematologyPACIFICOAlkylator Combination In Follicular lymphoma Immuno-Chemotherapy for Older patients: a phase III comparison of first-line R-CVP versus R-FC (previous acronym: RiCH FLO)Leeds Haematology
BradfordHaematologyPACIFICOAlkylator Combination In Follicular lymphoma Immuno-Chemotherapy for Older patients: a phase III comparison of first-line R-CVP versus R-FC (previous acronym: RiCH FLO)Bradford Haematology
HarrogateHaematologyPACIFICOAlkylator Combination In Follicular lymphoma Immuno-Chemotherapy for Older patients: a phase III comparison of first-line R-CVP versus R-FC (previous acronym: RiCH FLO)Harrogate Haematology
YorkHaematologyPACIFICOAlkylator Combination In Follicular lymphoma Immuno-Chemotherapy for Older patients: a phase III comparison of first-line R-CVP versus R-FC (previous acronym: RiCH FLO)York Haematology
Calderdale & Huddersfield HaematologyPACIFICOAlkylator Combination In Follicular lymphoma Immuno-Chemotherapy for Older patients: a phase III comparison of first-line R-CVP versus R-FC (previous acronym: RiCH FLO)C&H Haematology
LeedsHaematologyPADIMACPhase II study of Bortezomib, Adriamycin and Dexamethasone (PAD) therapy for previously untreated patients with
multiple myeloma: Impact of minimal residual disease (MRD) in patients with deferred ASCT (PADIMAC)
Leeds Haematology
LeedsPaediatricsPAETRPAETR Paediatric Trial Recruitment. Optimising recruitment to clinical trials in childhood cancer: perspectives of families and clinicians.Leeds Paediatrics
LeedsHaematologyPAIRedPAIReD (Pilot of Allogenic Immunotherapy in Refractory Disease): Phase II study of reduced intensity allogeneic
transplantation for refractory Hodgkin lymphoma
Leeds Haematology
LeedsGynaecologyPARP (BRCA)A Cancer Research UK Phase II Proof of Principle Trial of the activity of the intravenous PARP-1 inhibitor, AG-014699, in known carriers of a BRCA 1 or BRCA 2 mutation with locally advanced or metastatic breast or advanced ovarian cancerLeeds Gynaecology
LeedsUrologyPATCHProstate Adenocarcinoma: TransCutaneous Hormones. A randomised-controlled trial of transcutaneous oestrogen patches versus LHRH analogues in prostate cancerLeeds Urology
Mid YorkshireUrologyPATCHProstate Adenocarcinoma: TransCutaneous Hormones. A randomised-controlled trial of transcutaneous oestrogen patches versus LHRH analogues in prostate cancerMid Yorkshire Urology
Calderdale & HuddersfieldUrologyPATCHProstate Adenocarcinoma: TransCutaneous Hormones. A randomised-controlled trial of transcutaneous oestrogen patches versus LHRH analogues in prostate cancerC&H Urology
LeedsUrologyPEPCExperiences of penile cancer: understanding and improving patients’ experiences after treatment for penile cancerLeeds Urology
BradfordBreastPersephoneDuration of Trastuzumab with chemotherapy in women with early stage breast cancer: six months versus twelveBradford Breast
AiredaleBreastPersephoneDuration of Trastuzumab with chemotherapy in women with early stage breast cancer: six months versus twelveAiredale Breast
BradfordHead & NeckPET-NECKA multicentre randomised phase III trial comparing PET-CT guided watch and wait policy versus planned neck dissection for the management of locally advanced (N2/N3) nodal metastases in patients with head and neck squamous cancerBradford Head & Neck
LeedsHead and NeckPET-NECKA multicentre randomised phase III trial comparing PET-CT guided watch and wait policy versus planned neck dissection for the management of locally advanced (N2/N3) nodal metastases in patients with head and neck squamous cancerLeeds Head & Neck
LeedsPancreasPET-PANCThe impact of combined modality positron emission tomography with computerised tomography scanning (PET/CT) in
the diagnosis and management of pancreatic cancer.
Leeds Pancreas
LeedsGynaecologyPETROC/OV21A Phase II/III study of Intraperitoneal (IP) Plus Intravenous (IV) Chemotherapy Versus IV Carboplatin plus Paclitaxel in
Patients with Epithelial Ovarian Cancer Optimally Debulked at Surgery Following Neoadjuvant Intravenous
Chemotherapy
Leeds Gynaecology
LeedsPaediatricsPK 2006 07 (ActD in children)Pharmacokinetics of actinomycin D in children with cancerLeeds Paediatrics
LeedsPaediatricsPK 2006 09 (Infant PK)Pharmacokinetics and pharmacogenetics of anticancer drugs in infants and young childrenLeeds Paediatrics
Calderdale and HuddersfieldHaematologyPlace of care and death in haematological malignancyExploration of factors associated with place of care and place of death in patients with haematological malignanciesC&H Haematologytarget=”_blank”>Calderdale & Huddersfield Haematology
Mid YorkshireHaematologyPlace of care and death in haematological malignancyExploration of factors associated with place of care and place of death in patients with haematological malignanciesMid Yorkshire Haematology
YorkHaematologyPlace of care and death in haematological malignancyExploration of factors associated with place of care and place of death in patients with haematological malignanciesYork Haematology
HarrogateHaematologyPlace of care and death in haematological malignancyExploration of factors associated with place of care and place of death in patients with haematological malignanciesHarrogate Haematology
BradfordHaematologyPlace of care and death in haematological malignancyExploration of factors associated with place of care and place of death in patients with haematological malignanciesBradford Haematology
LeedsHaematologyPlace of care and death in haematological malignancyExploration of factors associated with place of care and place of death in patients with haematological malignanciesLeeds Haematology
Calderdale & HuddersfieldBreastPOETICTrial of Perioperative Endocrine Therapy - Individualising CareC&H Breast
LeedsBreastPOETICTrial of Perioperative Endocrine Therapy - Individualising CareLeeds Breast
HarrogateBreastPOETICTrial of Perioperative Endocrine Therapy - Individualising CareHarrogate Breast
Mid YorkshireBreastPOETICTrial of Perioperative Endocrine Therapy - Individualising CareMid Yorkshire Breast
BradfordBreastPOETICTrial of Perioperative Endocrine Therapy - Individualising CareBradford Breast
AiredaleBreastPOETICTrial of Perioperative Endocrine Therapy - Individualising CareAiredale Breast
LeedsColorectalPROSPECTIcmapnrocveinrg the prediction of metastatic disease in primary colorectal cancer: Prospective multicentre evaluation of a
prognostic model of conventional predictive variables and novel variables derived from perfusion computed tomography
Leeds Colorectal
BradfordColorectalPROSPECTIcmapnrocveinrg the prediction of metastatic disease in primary colorectal cancer: Prospective multicentre evaluation of a
prognostic model of conventional predictive variables and novel variables derived from perfusion computed tomography
Bradford Colorectal
YorkColorectalPROSPECTIcmapnrocveinrg the prediction of metastatic disease in primary colorectal cancer: Prospective multicentre evaluation of a
prognostic model of conventional predictive variables and novel variables derived from perfusion computed tomography
York Colorectal
Calderdale & HuddersfieldHaematologyPT1 (MRC)A Randomised Trial to compare Aspirin versus Hydroxyurea/ Aspirin in ‘Intermediate Risk’ Primary Thrombocythaemia and Aspirin only with Observation In ‘Low Risk’ Primary ThrombocythaemiaC&H Haematology
HarrogateHaematologyPT1 (MRC)A Randomised Trial to compare Aspirin versus Hydroxyurea/ Aspirin in ‘Intermediate Risk’ Primary Thrombocythaemia and Aspirin only with Observation In ‘Low Risk’ Primary ThrombocythaemiaHarrogate Haematology
Mid YorkshireHaematologyPT1 (MRC)A Randomised Trial to compare Aspirin versus Hydroxyurea/ Aspirin in ‘Intermediate Risk’ Primary Thrombocythaemia and Aspirin only with Observation In ‘Low Risk’ Primary ThrombocythaemiaMid Yorkshire Haematology
BradfordHaematologyPT1 (MRC)A Randomised Trial to compare Aspirin versus Hydroxyurea/ Aspirin in ‘Intermediate Risk’ Primary Thrombocythaemia and Aspirin only with Observation In ‘Low Risk’ Primary ThrombocythaemiaBradford Haematology
LeedsHaematologyPT1 (MRC)A Randomised Trial to compare Aspirin versus Hydroxyurea/ Aspirin in ‘Intermediate Risk’ Primary Thrombocythaemia and Aspirin only with Observation In ‘Low Risk’ Primary ThrombocythaemiaLeeds Haematology
AiredaleHaematologyPT1 (MRC)A Randomised Trial to compare Aspirin versus Hydroxyurea/Aspirin in ‘Intermediate Risk’ Primary Thrombocythaemia and Aspirin only with Observation In  ‘Low Risk’ Primary ThrombocythaemiaAiredale Haematology
LeedsColorectalPulMICCPulmonary Metastasectomy in Colorectal Cancer.
A Randomised feasibility study of Pulmonary Metastasectomy in Colorectal Cancer
Leeds Colorectal
LeedsUrologyQuality of life of long-term survivors of testicular cancerMethods and measures for assessing quality of life of mid- to long-term survivors of testicular and prostate cancer from
EORTC Phase III Clinical Trials
Leeds Urology
HarrogateLungQUARTZA phase III multicentre randomised controlled trial to assess whether optimal supportive care (including dexamethasone) alone is as effective as optimal supportive care (including dexamethasone) and whole brain radiotherapy (WBRT) in the treatment of patiHarrogate Lung
Calderdale & HuddersfieldLungQUARTZA phase III multicentre randomised controlled trial to assess whether optimal supportive care (including dexamethasone) alone is as effective as optimal supportive care (including dexamethasone) and whole brain radiotherapy (WBRT) in the treatment of patiC&H Lung
Mid YorkshireLungQUARTZA phase III multicentre randomised controlled trial to assess whether optimal supportive care (including dexamethasone) alone is as effective as optimal supportive care (including dexamethasone) and whole brain radiotherapy (WBRT) in the treatment of patiMid Yorkshire Lung
LeedsLungQUARTZA phase III multicentre randomised controlled trial to assess whether optimal supportive care (including dexamethasone) alone is as effective as optimal supportive care (including dexamethasone) and whole brain radiotherapy (WBRT) in the treatment of patiLeeds Lung
Calderdale & HudderfieldBreastQUEST Trial AA multi-centre randomised trial to assess the impact of the type of breast reconstruction on quality of life of women
following mastectomy for early breast cancer
C&H Breast
LeedsBreastQUEST Trial AA multi-centre randomised trial to assess the impact of the type of breast reconstruction on quality of life of women
following mastectomy for early breast cancer
Leeds Breast
YorkBreastQUEST Trial AA multi-centre randomised trial to assess the impact of the type of breast reconstruction on quality of life of women
following mastectomy for early breast cancer
York Breast
LeedsBreastQUEST Trial BA multi-centre randomised trial to assess the impact of the timing of breast reconstruction on quality of life of women
following mastectomy for early breast cancer
Leeds Breast
Calderdale & HuddersfieldBreastQUEST Trial BA multi-centre randomised trial to assess the impact of the timing of breast reconstruction on quality of life of women
following mastectomy for early breast cancer
C&H Breast
YorkBreastQUEST Trial BA multi-centre randomised trial to assess the impact of the timing of breast reconstruction on quality of life of women
following mastectomy for early breast cancer
York Breast
LeedsHaematologyR-CODOX-M/IVAC for DLBCLA Phase II Single Arm Study of the use of CODOX-M/IVAC with Rituximab (R-CODOX-M/IVAC) in the treatment of patients with Diffuse Large B-Cell Lymphoma (DLBCL) or Burkitt's Lymphoma (BL) of International Prognostic Index High or High-Intermediate RiskLeeds Haematology
BradfordHaematologyR-CODOX-M/IVAC for DLBCLA Phase II Single Arm Study of the use of CODOX-M/IVAC with Rituximab (R-CODOX-M/IVAC) in the treatment of patients with Diffuse Large B-Cell Lymphoma (DLBCL) or Burkitt's Lymphoma (BL) of International Prognostic Index High or High-Intermediate RiskBradford Haematology
Mid YorkshireHaematologyR-CODOX-M/IVAC for DLBCLA Phase II Single Arm Study of the use of CODOX-M/IVAC with Rituximab (R-CODOX-M/IVAC) in the treatment of patients with Diffuse Large B-Cell Lymphoma (DLBCL) or Burkitt's Lymphoma (BL) of International Prognostic Index High or High-Intermediate RiskMid Yorkshire Haematology
LeedsUrologyRADICALS (MRC PR10)Radiotherapy and Androgen Deprivation In Combination After Local SurgeryLeeds Urology
YorkUrologyRADICALS (MRC PR10)Radiotherapy and Androgen Deprivation In Combination After Local SurgeryYork Urology
BradfordUrologyRADICALS (MRC PR10)Radiotherapy and Androgen Deprivation In Combination After Local SurgeryBradford Urology
AiredaleUrologyRADICALS (MRC PR10)Radiotherapy and Androgen Deprivation In Combination After Local SurgeryAiredale Urology
Mid YorkshireUrologyRADICALS (MRC PR10)Radiotherapy and Androgen Deprivation In Combination After Local SurgeryMid Yorkshire Urology
Mid YorkshireUrologyRAPPERRadiogenomics: assessment of polymorphisms for predicting the effects of radiotherapyMid Yorkshire Urology
LeedsUrologyRAPPERRadiogenomics: assessment of polymorphisms for predicting the effects of radiotherapyLeeds Urology
BradfordUrologyRAPPERRadiogenomics: assessment of polymorphisms for predicting the effects of radiotherapyBradford Urology
YorkHaematologyRATHLA randomised phase III trial to assess response adapted therapy using FDG-PET imaging in patients with newly diagnosed, advanced hodgkin lymphomaYork Haematology
Mid YorkshireHaematologyRATHLA randomised phase III trial to assess response adapted therapy using FDG-PET imaging in patients with newly diagnosed, advanced hodgkin lymphomaMid Yorkshire Haematology
Calderdale & Huddersfield HaematologyRATHLA randomised phase III trial to assess response adapted therapy using FDG-PET imaging in patients with newly diagnosed, advanced hodgkin lymphomaC&H Haematology
LeedsHaematologyRATHLA randomised phase III trial to assess response adapted therapy using FDG-PET imaging in patients with newly diagnosed, advanced hodgkin lymphomaLeeds Haematology
LeedsHaematologyReACHReACH (Reduced Intensity Allografting for Chemosensitive Hodgkin Lymphoma): Phase II study of reduced intensity
sibling allogeneic transplantation for relapsed, chemosensitive, PET positive Hodgkin lymphoma
Leeds Haematology
AiredaleBreastREACTA phase III multicentre double blind randomised trial of celecoxib versus placebo in primary breast cancer patientsAiredale Breast
BradfordHaematologyREMoDLBA randomised evaluation of molecular guided therapy for diffuse large B-cell lymphoma with BortezomibBradford Haematology
LeedsHaematologyREMoDLBA randomised evaluation of molecular guided therapy for diffuse large B-cell lymphoma with BortezomibLeeds Haematology
HarrogateHaematologyREMoDLBA randomised evaluation of molecular guided therapy for diffuse large B-cell lymphoma with BortezomibHarrogate Haematology
AiredaleLungReSoLuCENTResource for the Study of Lung Cancer Epidemiology in North TrentAiredale Lung
LeedsLungRESTA Randomised Trial on Chest Irradiation in Extensive Disease Small Cell Lung Cancer (ED-SCLCLeeds Lung
LeedsHaematologyRIC UCBTTransplantation of umbilical cord blood from unrelated donors in patients with haematological diseases using a reduced intensity conditioning regimenLeeds Haematology
LeedsColorectalROLARRAn international multicentre, prospective, randomised, controlled, unblinded, parallel-group trial of robotic-assisted
versus standard laparoscopic surgery for the curative treatment of rectal cancer
Leeds Colorectal
Calderdale & Huddersfield GynaecologyRT3 VINA Randomised Trial of Topical Treatment in Women with Vulval Intraepithelial NeoplasiaC&H Gynaecology
LeedsGynaecologyRT3 VINA Randomised Trial of Topical Treatment in Women with Vulval Intraepithelial NeoplasiaLeeds Gynaecology
LeedsGynaecologySaPPrOCA randomised placebo-controlled trial of Saracatinib (AZD0530) plus weekly paclitaxel in platinum resistant ovarian,
fallopian tube or primary peritoneal cancer
Leeds Gynaecology
BradfordColorectalSCOTShort Course Oncology Therapy - A study of Adjuvant Chemotherapy in colorectal cancer by the CACTUS & QUASAR 3
Groups
Bradford Colorectal
YorkColorectalSCOTShort Course Oncology Therapy - A study of Adjuvant Chemotherapy in colorectal cancer by the CACTUS & QUASAR 3
Groups
York Colorectal
AiredaleColorectalSCOTShort Course Oncology Therapy - A study of Adjuvant Chemotherapy in colorectal cancer by the CACTUS & QUASAR 3
Groups
Airedale Colorectal
LeedsColorectalSCOTShort Course Oncology Therapy - A study of Adjuvant Chemotherapy in colorectal cancer by the CACTUS & QUASAR 3
Groups
Leeds Colorectal
HarrogateColorectalSCOTShort Course Oncology Therapy - A study of Adjuvant Chemotherapy in colorectal cancer by the CACTUS & QUASAR 3
Groups
Harrogate Colorectal
LeedsUrologySORCEA phase III Randomised Controlled Study Comparing Sorafenib With Placebo In Patients With Resected Primary Renal Cell Carcinoma at High or Intermediate Risk of RelapseLeeds Urology
YorkHaematologySPIRIT 2STI571 Prospective International RandomIsed Trial 2: A phase III, prospective randomised comparison of imatinib (STI571, Glivec/Gleevec) 400mg daily versus dasatinib (Sprycel) 100mg daily in patients with newly-diagnosed chronic phase chronic myeloid leukYork Haematology
HarrogateHaematologySPIRIT 2STI571 Prospective International RandomIsed Trial 2: A phase III, prospective randomised comparison of imatinib (STI571, Glivec/Gleevec) 400mg daily versus dasatinib (Sprycel) 100mg daily in patients with newly-diagnosed chronic phase chronic myeloid leukHarrogate Haematology
Mid YorkshireHaematologySPIRIT 2STI571 Prospective International RandomIsed Trial 2: A phase III, prospective randomised comparison of imatinib (STI571, Glivec/Gleevec) 400mg daily versus dasatinib (Sprycel) 100mg daily in patients with newly-diagnosed chronic phase chronic myeloid leukMid Yorkshire Haematology
BradfordHaematologySPIRIT 2STI571 Prospective International RandomIsed Trial 2: A phase III, prospective randomised comparison of imatinib (STI571, Glivec/Gleevec) 400mg daily versus dasatinib (Sprycel) 100mg daily in patients with newly-diagnosed chronic phase chronic myeloid leukBradford Haematology
AiredaleHaematologySPIRIT 2STI571 Prospective International RandomIsed Trial 2: A phase III, prospective randomised comparison of imatinib (STI571, Glivec/Gleevec) 400mg daily versus dasatinib  (Sprycel) 100mg daily in patients with newly-diagnosed chronic phase chronic myeloid leukAiredale Haematology
LeedsHaematologySPIRIT 2STI571 Prospective International RandomIsed Trial 2: A phase III, prospective randomised comparison of imatinib (STI571, Glivec/Gleevec) 400mg daily versus dasatinib (Sprycel) 100mg daily in patients with newly-diagnosed chronic phase chronic myeloid leukLeeds Haematology
LeedsUpper GIST03A Randomised Phase III trial of Peri-operative Chemotherapy with or without Bevacizumab in Operable Adenocarcinoma of the Stomach and Gastro-oesophageal JunctionLeeds Upper GI
BradfordUpper GIST03A Randomised Phase III trial of Peri-operative Chemotherapy with or without Bevacizumab in Operable Adenocarcinoma of the Stomach and Gastro-oesophageal JunctionBradford Upper GI
AiredaleUpper GIST03A Randomised Phase III trial of Peri-operative Chemotherapy with or without Bevacizumab in Operable Adenocarcinoma of the Stomach and Gastro-oesophageal JunctionAiredale Upper GI
Calderdale & HuddersfieldUpper GIST03A Randomised Phase III trial of Peri-operative Chemotherapy with or without Bevacizumab in Operable Adenocarcinoma of the Stomach and Gastro-oesophageal JunctionC&H Upper GI
Calderdale & HuddersfieldUrologySTAMPEDESystemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug EfficacyC&H Urology
LeedsUrologySTAMPEDESystemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug EfficacyLeeds Urology
AiredaleUrologySTAMPEDESystemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug EfficacyAiredale Urology
BradfordUrologySTAMPEDESystemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug EfficacyBradford Urology
LeedsUrologySTARSTAR: A Randomised MultiStage Phase II/III trial of Sunitinib comparing Temporary cessation with Allowing continuation,
at the time of maximal radiological response, in the firstline treatment of locally advanced and/or metastatic Renal
cancer
Leeds Urology
LeedsPaediatricsSTS 2006 03 (NRSTS)EpSSG NRSTS 2005 - A protocol for localised non-rhabdomyosarcoma soft tissue sarcomasLeeds Paediatrics
LeedsPaediatricsSTS 2006 04 RMS 2005EpSSG RMS 2005 a protocol for non metastatic rhabdomyosarcoma (European Paediatric Soft Tissue Sarcoma Study
Group)
Leeds Paediatrics
LeedsUrologySUCCINTA Phase II single-arm trial to evaluate cisplatin and gemcitabine chemotherapy in combination with sunitinib for first-line
treatment of patients with advanced transitional carcinoma of the urothelium.
Leeds Urology
Mid YorkshireBreastSUPREMOSelective use of postmastectomy radiotherapy after mastectomyMid Yorkshire Breast
LeedsBreastSUPREMOSelective use of postmastectomy radiotherapy after mastectomyLeeds Breast
LeedsUrologySurtime - EORTC 30073EORTC 30073 Randomized Phase III trial comparing immediate versus deferred nephrectomy in patients with synchronous metastatic renal cell carcinoma.Leeds Urology
LeedsHaematologyThe Causes of Clonal Blood Cell Disorders (Adults)The Causes of Clonal Blood Cell DisordersLeeds Haematology
LeedsPaediatricsThe Causes of Clonal Blood DisordersThe Causes of Clonal Blood Cell DisordersLeeds Paediatrics
AiredaleSkinThe Melanoma Lifestyle StudyThe Melanoma Lifestyle StudyMelanoma/Skin
HarrogateSkinThe Melanoma Lifestyle StudyThe Melanoma Lifestyle StudyMelanoma/Skin
LeedsSkinThe Melanoma Lifestyle StudyThe Melanoma Lifestyle StudyMelanoma/Skin
Mid YorkshireColorectalThe seAFOod Polyp Prevention TrialA randomised controlled trial of eicosapentaenoic acid (EPA) and/or aspirin for colorectal adenoma (or polyp)
prevention during colonoscopic surveillance in the NHS Bowel Cancer Screening Programme: The seAFOod (Systematic
Evaluation of Aspirin and Fish O
Mid Yorkshire Colorectal
BradfordColorectalThe seAFOod Polyp Prevention TrialA randomised controlled trial of eicosapentaenoic acid (EPA) and/or aspirin for colorectal adenoma (or polyp)
prevention during colonoscopic surveillance in the NHS Bowel Cancer Screening Programme: The seAFOod (Systematic
Evaluation of Aspirin and Fish O
Bradford Colorectal
YorkColorectalThe seAFOod Polyp Prevention TrialA randomised controlled trial of eicosapentaenoic acid (EPA) and/or aspirin for colorectal adenoma (or polyp)
prevention during colonoscopic surveillance in the NHS Bowel Cancer Screening Programme: The seAFOod (Systematic
Evaluation of Aspirin and Fish O
York Colorectal
AiredaleColorectalThe seAFOod Polyp Prevention TrialA randomised controlled trial of eicosapentaenoic acid (EPA) and/or aspirin for colorectal adenoma (or polyp)
prevention during colonoscopic surveillance in the NHS Bowel Cancer Screening Programme: The seAFOod (Systematic
Evaluation of Aspirin and Fish O
Airedale Colorectal
LeedsUrologyThe UK Genetics of Testicular Cancer StudyIdentification of testicular germ cell tumour susceptibility genesLeeds Urology
LeedsUrologyThe UK Genetics of Testicular Cancer StudyIdentification of testicular germ cell tumour susceptibility genesLeeds Urology
LeedsLungTIME3Adjuvant Urokinase in the Treatment of Malignant Pleural Effusion: The Third Therapeutic Intervention in Malignant
Effusion Trial (TIME3-UK). (A Randomised Controlled Trial to evaluate whether use of intrapleural Urokinase aids the
drainage of multi-septa
Leeds Lung
LeedsLungTIPSTHE INHALED PARTICLES STUDYLeeds Lung
AiredaleBreastTNTTriple Negative Breast Cancer Trial: A randomised phase III trial of carboplatin compared to docetaxel for patients with
metastatic or recurrent locally advanced ER-, PR-and HER2- or known BRCA1 or BRCA2 mutation associated breast
cancer.
Airedale Breast
LeedsBreastTNTTriple Negative Breast Cancer Trial: A randomised phase III trial of carboplatin compared to docetaxel for patients with
metastatic or recurrent locally advanced ER-, PR- and HER2- or known BRCA1 or BRCA2 mutation associated breast
cancer.
Leeds Breast
BradfordBreastTNTTriple Negative Breast Cancer Trial: A randomised phase III trial of carboplatin compared to docetaxel for patients with
metastatic or recurrent locally advanced ER-, PR- and HER2- or known BRCA1 or BRCA2 mutation associated breast
cancer.
Bradford Breast
Calderdale & HuddersfieldUrologyTOUCANVandetanib in non-cisplatin fit patients with urothelial cancers -A randomised phase II Trial of carboplatin and gemcitabine +/- vandetanib in first line treatment Of advanced Urothelial cell Cancer in patients who are not suitable to receive cisplatinC&H Urology
LeedsUrologyTOUCANVandetanib in non-cisplatin fit patients with urothelial cancers -A randomised phase II Trial of carboplatin and gemcitabine +/- vandetanib in first line treatment Of advanced Urothelial cell Cancer in patients who are not suitable to receive cisplatinLeeds Urology
LeedsPaediatricsTRANSCALTranslational Study for Children and Adolescents with Low Grade GliomaLeeds Paediatrics
LeedsUrologyTRANSORCEA study to collect blood and tissue samples from consenting patients who have been diagnosed with renal cell cancer.Leeds Urology
BradfordColorectalTRECTransanal Endoscopic Microsurgery (TEM) and Radiotherapy in Early Rectal CancerBradford Colorectal
LeedsColorectalTRECTransanal Endoscopic Microsurgery (TEM) and Radiotherapy in Early Rectal CancerLeeds Colorectal
LeedsUrologyTRISST (MRC TE24)Trial of imaging and schedule in seminoma testisLeeds Urology
Mid YorkshireHaematologyUKALL 14A randomized trial for adults with newly diagnosed acute lymphoblastic leukaemia Mid Yorkshire Haematology
LeedsHaematologyUKALL 14A randomized trial for adults with newly diagnosed acute lymphoblastic leukaemiaLeeds Haematology
LeedsHaematologyUKALL 2011A randomized trial for adults with newly diagnosed acute lymphoblastic leukaemia Leeds Haematology
BradfordHaematologyUKALL 14A randomized trial for adults with newly diagnosed acute lymphoblastic leukaemia Bradford Haematology
LeedsPaediatricsUKALL 2011United Kingdom National Randomised Trial for Children and Young Adults with Acute Lymphoblastic Leukaemia and
Lymphoma 2011
Leeds Paediatrics
HarrogateUrologyUK GPCSUK Genetic Prostate Cancer StudyHarrogate Urology
LeedsUrologyUK GPCSUK Genetic Prostate Cancer StudyLeeds Urology
YorkUrologyUK GPCSUK Genetic Prostate Cancer StudyYork Urology
Mid YorkshireUrologyUK GPCSUK Genetic Prostate Cancer StudyMid Yorkshire Urology
Calderdale & HuddersfieldUrologyUK GPCSUK Genetic Prostate Cancer StudyC&H Urology
BradfordUrologyUK GPCSUK Genetic Prostate Cancer StudyBradford Urology
AiredaleUrologyUK GPCSUK Genetic Prostate Cancer StudyAiredale Urology
 
 
Disclaimer: The Yorkshire Cancer Research Network make every reasonable effort to ensure that all information provided by us is accurate at the time of its inclusion. From time to time there may be errors, inaccuracies or omissions and we cannot accept liability for these. Whilst we can make available information about clinical trials we cannot facilitate the recruitment of patients on to trials. Although we provide links to other websites we are unable to accept responsibility for their content or any resources linked to this website; neither can we endorse their content, products or services.